

LITERATURA

1. Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. *Med Genet*. 2016;53:145-151.
2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy. *Lancet Neurology*. 2018.
3. Bönnemann CG, Belluscio BA, Braun S, et al. Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy. *N Engl J Med*. 2023;388(24):2294-2296.
4. European Medicines Agency (EMA) (online) https://www.ema.europa.eu/en/documents/product-information/libmel-dy-epar-product-information_en.pdf.
5. European Medicines Agency (EMA) (online) https://www.ema.europa.eu/en/documents/product-information/zolgensma-epar-product-information_en.pdf.
6. Hoon Lee B, Deng S, Chiriboga CA, et al. Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years. *Neurology*. 2022;99(14):e1527-e1537.
7. International Commission on the Clinical Use of Human Germline Genome Editing. Heritable Human Genome Editing. Kniha. 2020.
8. Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. *Eur J Paediatr Neurol*. 2020;28:38-43.
9. Kirschner J, Bernert G, Butoianu N, et al. Update: European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. *Eur J Paediatr Neurol*. 2024;51:73-78.
10. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukemia following gene therapy of X-linked SCID. *Nat Rev Cancer*. 2003;3(7):477-88.
11. Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. *European Journal of Epidemiology*. 2020;35:643-653.
12. Lugoowska A, Poninska J, Krajewski P, et al. Population carrier rates of pathogenic ARSA gene mutations: is metachromatic leukodystrophy underdiagnosed? *PLoS One*. 2011;6(6):e20218.
13. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Apeparovect in Spinal Muscular Atrophy. *JAMA Neurol*. 2021;78(7):834-841.
14. Nařízení Evropského parlamentu a rady (ES) č. 1394/2007. Úřední věstník Evropské unie. 2007.
15. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. *The Lancet*. 2014;383(9923):1138-1146.
16. Philippidis A. Novartis Confirms Deaths of 2 Patients Treated with Gene Therapy Zolgensma. Genetic Engineering & Biotechnology News August 12, 2022.
17. Rare Disease Database. X-linked adrenoleukodystrophy. National Organization for Rare Diseases. <https://rarediseases.org/rare-diseases/adrenoleukodystrophy/>. Published 2019. Accessed October 26, 2022.
18. Rosenberg SA, Aebbersold P, Cornetta K, et al. Gene Transfer into Humans – Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction. *N Engl J Med*. 2003;349:1018-1027.
19. Sehara Y, Fujimoto KI, Ikeguchi K. Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease. *Hum Gene Ther Clin Dev*. 2017;28(2):74-79.
20. Shaimardanova AA, Chulpanova DS, Solovyeva VV, et al. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. *Front. Med.*, 2020.
21. Shaimardanova AA, Chulpanova DS, Mulagovova AL, et al. Gene and Cell Therapy for Epilepsy: A Mini Review. *Front. Mol. Neurosci.*, 11 May 2022.
22. Stolberg, Sheryl Gay (November 28, 1999). "The Biotech Death of Jesse Gelsinger". *The New York Times Magazine*.
23. Turner TJ, Zourray C, Schorge S, et al. Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. *J Neurochem*. 2021;157(2):229-262.
24. US Food and Drug Administration (online) <https://www.fda.gov/vaccines-blood-biologics/skysona>.
25. US Food and Drug Administration (online) <https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy>.
26. US Food and Drug Administration (online) <https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevydis>.
27. Verhaart ECI, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. *Orphanet Journal of Rare Diseases*. 2017;12:124.
28. Vision research report (online) <https://www.visionresearchreports.com/cell-and-gene-therapy-market/39387>.
29. Vockley J, Brunetti-Pierri N, Chung WK, et al. The evolving role of medical geneticists in the era of gene therapy: An urgency to prepare. *Genetics in Medicine*. 2023;25:100022.
30. Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. *Orphanet Journal of Rare Diseases* (2017).
31. Wadbudhe AM, Meshram RJ, Tidke SC. Severe Combined Immunodeficiency (SCID) and Its New Treatment Modalities. *Cureus*. 2023 Oct;15(10): e47759.
32. Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. *Orphanet Journal of Rare Diseases*. 2017;12:1229.
33. Yin-Hsiu Ch, Ni-Chung L, Sheng-Hong T, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. *Lancet Child Adolesc Health*. 2017 Dec;1(4):265-273.
34. Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. *Drug Discov Today*. 2022;27(1):17-30.

Právě jste dokončili studium medicíny?

Máme pro vás odborný kongres zcela zdarma.



SOLEN MEDICAL EDUCATION

